# Supernus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/supernus-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Rockville, US
- Website: www.supernus.com
- Total disclosed funding: $49M
- Latest round: Series A (Jan 12, 2006)
- Investors on record: 3

## About

Supernus Pharmaceuticals, Inc. is dedicated to developing innovative pharmaceuticals targeting central nervous system disorders, including ADHD and epilepsy, enhancing treatment options for affected patients.Supernus Pharmaceuticals, Inc. was established in 2005 in Rockville, US, focusing on CNS treatments. The company underwent a strategic shift, divesting its subsidiary, TCD Royalty, for USD 27 mn in December 2011. In May 2012, Supernus completed its IPO, raising USD 50 mn. The company is led by CEO Jack Khattar, who has experience in founding and leading pharmaceutical ventures.Supernus Pharmaceuticals specializes in the development and commercialization of innovative treatments for central nervous system (CNS) diseases. Their core product offerings include a range of pharmaceuticals designed to address conditions such as attention-deficit hyperactivity disorder (ADHD) and epilepsy. Notable products in their portfolio include Qelbree™, which is specifically aimed at providing a non-stimulant treatment option for ADHD, and other therapies that focus on improving health outcomes for patients suffering from CNS disorders. Supernus actively targets healthcare providers, patients, and caregivers as its primary customer base, ensuring that its solutions meet the substantial health needs of individuals with CNS diseases. Their products are distributed in North America and select international markets, reflecting a commitment to expand access to effective CNS treatments globally.Supernus Pharmaceuticals generates revenue through sales of its prescription medications, with a focus on direct transactions with healthcare providers and pharmacies. The company's revenue from sales reached USD 637.70 mn in 2024, with an EBITDA of USD 163.90 mn. Pricing structures for their flagship products, such as Qelbree™, are determined based on market factors and competitive positioning, allowing the company to maintain a steady flow of revenue from their established product lines. The company's strategic focus on CNS disorders positions it well within a niche but growing market, driving consistent demand for its therapeutic offerings.Supernus Pharmaceuticals is focused on expanding its presence in the CNS treatment market by launching new products and entering additional geographical regions. The company aims to enhance its portfolio with upcoming offerings designed to address unmet medical needs in CNS diseases. The recent IPO funding of USD 50 mn will be instrumental in supporting these initiatives. Additionally, Supernus plans to explore new markets beyond North America, with specific strategies to be implemented by the end of 2024.

## Funding rounds

- Series A, Jan 12, 2006, $49M — Abingworth, New Enterprise Associates, OrbiMed Advisors

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A